正文
英文标题：Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase 3 clinical trial (ANCHOR trial)
大会发言：北京大学肿瘤医院 齐长松
大会专场：Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
摘要号：4003
报告类型：ORAL
中文标题：Claudin18.2-CAR T 细胞（Satri-cel） vs 医生选择的治疗 (TPC) 用于经治的晚期胃或胃食管连接部癌 (G/GEJC)：一项随机、开放标签、II 期试验 (CT041-ST-01) 的主要结果
英文标题：Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01).
大会发言：北京大学肿瘤医院 张盼盼
大会专场：Developmental Therapeutics—Immunotherapy
摘要号：2500
报告类型：ORAL
中文标题：评估LBL-024 (一种针对PD-L1和4-1BB的新型双特异性抗) 联合依托泊苷/铂类化疗治疗未经治疗的晚期肺外神经内分泌癌（EP-NEC）的疗效：一项多中心Ib/II期试验
英文标题：Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.
大会发言：复旦大学附属中山医院 许剑民
大会专场：Gastrointestinal Cancer—Colorectal and Anal
摘要号：LBA3516
报告类型：RAPID ORAL
中文标题：JMT101 联合伊立替康和 SG001 vs 瑞戈非尼治疗转移性结直肠腺癌 (mCRC) 患者：一项随机、对照、开放标签 II 期研究的结果
英文标题：JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC): Results of a randomized, controlled, open-label, phase II study
大会发言：山东第一医科大学附属省立医院 靖昌庆
大会专场：Gastrointestinal Cancer—Colorectal and Anal
